Light‐chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A

aortic stenosis. N Engl J Med 1958; 259: 196. 5 Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758–61. 6 Rauch R, Budde U, Koch A, Girisch M, Hofbeck M. Acquired von Willebrand syndrome in children with patent ductus arteriosus. Heart 2002; 88: 87–8. 7 Arslan MT, Ozyurek R, Kavakli K. et al. Frequency of acquired von Willebrand’s disease in children with congenital heart disease. Acta Cardiol 2007; 62: 403–8. 8 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777–85. 9 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6: 569–76. 10 Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003; 25: 874–9.

[1]  L. Hoyer,et al.  Hemophilia A. , 2020, The New England journal of medicine.

[2]  M. Gertz,et al.  Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment , 2014, American journal of hematology.

[3]  D. Seldin,et al.  Immunoglobulin light chain amyloidosis , 2014, Expert review of hematology.

[4]  G. Tjønnfjord,et al.  Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  D. Lillicrap,et al.  Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[6]  A. Tosetto,et al.  Bleeders, bleeding rates, and bleeding score , 2013, Journal of thrombosis and haemostasis : JTH.

[7]  F. Ataullakhanov,et al.  Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. , 2013, Thrombosis research.

[8]  M. Gertz,et al.  Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment , 2013, American journal of hematology.

[9]  D. Lipsker,et al.  Haemorrhage and amyloidosis ― response to Veneri et al , 2013, British journal of haematology.

[10]  G. Rivard,et al.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  M. Gorman Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus–ataxia syndrome , 2010, Current opinion in pediatrics.

[12]  K. Mann,et al.  Thrombin generation and bleeding in haemophilia A , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  P. D. de Groot,et al.  Phenotypic heterogeneity in severe hemophilia , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  R. Santler,et al.  [Prognosis and treatment of lip cancer]. , 1969, Zeitschrift fur Haut- und Geschlechtskrankheiten.

[15]  L. Hoyer Medical progress : hemophilia A , 1994 .